| Turning the corner on therapeutic cancer vaccines |
77 |
| Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want |
39 |
| Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations |
26 |
| Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation |
21 |
| The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial |
21 |
| From therapeutic antibodies to immune complex vaccines |
20 |
| Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness |
19 |
| Recent advances in the production of recombinant glycoconjugate vaccines |
18 |
| LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection |
15 |
| A prophylactic alpha-Gal-based glycovaccine effectively protects against murine acute Chagas disease |
14 |
| Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females |
13 |
| Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques |
13 |
| Safety and efficacy of novel malaria vaccine regimens of RTS, S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP |
12 |
| A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection |
12 |
| Plague vaccine: recent progress and prospects |
11 |
| AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization |
11 |
| Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies |
11 |
| Successful application of prime and pull strategy for a therapeutic HSV vaccine |
11 |
| Q beta Virus-like particle-based vaccine induces robust immunity and protects against tauopathy |
11 |
| Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial |
11 |
| An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice |
10 |
| Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission |
10 |
| Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology |
10 |
| Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination |
10 |
| A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice |
9 |
| Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
9 |
| A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13 |
9 |
| A Plasmodium berghei sporozoite-based vaccination platform against human malaria |
8 |
| The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine |
7 |
| Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge |
7 |
| Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230 |
7 |
| Induction of neutralizing antibody response against koala retrovirus (KoRV) and reduction in viral load in koalas following vaccination with recombinant KoRV envelope protein |
7 |
| Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development |
7 |
| Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
7 |
| The how's and what's of vaccine reactogenicity |
7 |
| Rabies-based vaccine induces potent immune responses against Nipah virus |
6 |
| Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus |
6 |
| Bi-valent polysaccharides of Vi capsular and O9 O-antigen in attenuated Salmonella Typhimurium induce strong immune responses against these two antigens |
6 |
| Activation of the endoplasmic reticulum stress sensor IRE1 alpha by the vaccine adjuvant AS03 contributes to its immunostimulatory properties |
5 |
| Design and production of conjugate vaccines against S. Paratyphi A using an O-linked glycosylation system in vivo |
5 |
| Selection and evaluation of an efficient method for the recovery of viral nucleic acid extraction from complex biologicals |
5 |
| A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs |
5 |
| Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial |
5 |
| Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations |
5 |
| Recombinant measles vaccine expressing malaria antigens induces long-term memory and protection in mice |
5 |
| A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system |
5 |
| Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media |
5 |
| Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein |
4 |
| A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains |
4 |
| Generation of therapeutic antisera for emerging viral infections |
4 |
